Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Share News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.50
Bid: 19.00
Ask: 20.00
Change: -1.75 (-8.24%)
Spread: 1.00 (5.263%)
Open: 21.25
High: 21.25
Low: 19.00
Prev. Close: 21.25
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: CVS plunges on CMA vet probe; Angle ascends

Thu, 07th Sep 2023 11:20

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

----------

AIM - WINNERS

----------

Angle PLC, up 21% 13.87p, 120-month range pence, 12-month range 10.65p-75.25p. The medical diagnostics company says revenue in the first half trebles to GBP1.2 million from GBP419,000 a year before, as pretax loss widens to GBP10.6 million from GBP10.5 million. Says its pipeline for products and services businesses is building well, and momentum is expected to continue into the second half. Annual revenue is expected to be in line with market expectations. Also notes headline results for its major clinical studies are expected by the end of the year, and will demonstrate the key clinical applications of its liquid biopsy system Parasortix in patient care. Cash will be ahead of forecasts at the end of the year, thanks to careful control of costs and the deferral of some discretionary expenditure. This will extend the firm's cash runway into the first quarter of 2025, without affecting revenue in the next 24 months, Angle says. The stock is down 80% over the past 12 months, however.

----------

Directa Plus PLC, up 20% at 52p, 12-month range 43p-108p. The graphene product maker's environmental services subsidiary Sectar SA signs three-year contract to process oily mills sludge with Liberty Galati, the largest integrated steel producer in Romania. Contract is worth a total of EUR5.5 million, with potential for further expansion up to a total of EUR8.0 million. Setcar will provide solutions for the treatment of oily mills scale produced in the manufacturing of steel. Directa says the contract would enable Setcar to expand further its waste treatment and disposal services for industrial pollutants and broaden the range of applications for the group's Grafysorber technology. CEO Giulio Cesareo says the contract is the largest to date and a "very exciting win". It is equivalent to the firm's entire turnover in 2020, he adds.

----------

AIM - LOSERS

----------

CVS Group PLC, down 27% at 1,524p, 12-month range 1,365p-2,226p. The veterinary services firm plunges as the UK competition regulator kicks off a probe into the vet sector. The Competition & Markets Authority is launching a review of the sector, looking at consumer experiences and vet business practices for household pets in the UK. It cites concerns that pet owners are not getting value for money, and the rising costs of pet care have risen faster than wider inflation. Pets at Home Group PLC shares are also down 9.5%, with the retailer also operating veterinary surgeries and practices. "The sell-off seen today could be an overreaction, although the CMA review looks to be wide-ranging. The problem for both businesses is the process is likely to be time-consuming and, with a further update not due until early 2024, it could weigh on both stocks for some time to come," says AJ Bell investment director Russ Mould.

----------

Polarean Imaging PLC, down 18% at 11.85p, 12-month range 10.41p-84.2p. The medical imaging technology developer withdraws its commercial targets, with its CEO of three months Christopher von Jako citing his experience that "early sales are often irregular and difficult to forecast" during the commercialisation process. "While I am confident in the demand for our product and its ability to gain commercial traction, we feel it is sensible to withdraw the previously stated commercial targets at this time. We will, however, be providing renewed guidance at a suitable time," he says. In the first half of 2023, revenue drops to USD142,384 from USD834,087 a year before, as pretax loss widens to USD7.4 million from USD6.9 million.

----------

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 10:52

AIM WINNERS & LOSERS: Fletcher King optimistic; Angle in Astra deal

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
3 May 2024 08:48

LONDON MARKET OPEN: Confident start before US jobs data

(Alliance News) - Stock prices in London opened higher on Friday, on the rising conviction that the afternoon's US jobs report will be softer, cooling some hawkish Federal Reserve interest rate expectations.

Read more
3 May 2024 07:58

Angle strikes supplier deal with AstraZeneca

(Sharecast News) - Liquid biopsy technology firm Angle has struck a supplier deal with pharmaceutical giant AstraZeneca to develop an androgen receptor detection assay to enhance prostate cancer studies.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
24 Apr 2024 17:06

CORRECT: No record close for FTSE 100; mixed trade in US

(Correcting day of the week in the opening sentence.)

Read more
24 Apr 2024 17:00

LONDON MARKET CLOSE: No record close for FTSE 100; mixed trade in US

(Alliance News) - Stock prices in London closed lower on Thursday, with the FTSE 100's recent rally taking a pause for breath, but not after hitting another record high.

Read more
24 Apr 2024 10:32

Angle shares jump on supplier agreement with with AstraZeneca

(Alliance News) - Angle PLC shares rose on Wednesday, after it signed a contract with AstraZeneca PLC.

Read more
24 Apr 2024 10:10

AIM WINNERS & LOSERS: Filtronic jumps as lifts outlook

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
22 Apr 2024 16:52

IN BRIEF: Angle granted patents in US and Europe for Cellkeep slide

Angle PLC - Surrey-based medical diagnostics provider - Says it has been granted a European and US patent for its CellKeep slide. "We are delighted to have secured intellectual property rights for our proprietary CellKeep slide in two major jurisdictions....This is a significant technology advancement for the [circulating tumor cell] liquid biopsy field and another step towards enabling biomarker-guided precision medicine for people with cancer," says Chief Executive Officer Andrew Newland. The CellKeep slide was developed by Angle to reduce cell loss during the transfer of CTCs to the microscope slide and to protect the morphology of the harvested cells.

Read more
22 Apr 2024 06:59

Angle granted European patent for CellKeep, US patent imminent

(Sharecast News) - Liquid biopsy specialist Angle announced on Monday that it has received a European patent for its 'CellKeep' slide, as it anticipated the imminent grant of an equivalent US patent application.

Read more
22 Jan 2024 18:03

IN BRIEF: Angle highlights supportive data for DNA analysis tool

Angle PLC - Surrey-based medical diagnostics provider - Announces publication of a peer-reviewed paper in a special issue of the journal - "Current Issues in Molecular Biology" Special Issue: Advanced Solutions for Cancer Therapy. Article brings together supporting evidence for the additional and complementary information that can be obtained from circulating tumour cells, demonstrating the value of a dual analyte approach for both CTCs and ctDNA (fragments of DNA released mainly by dying cells). Angle recently announced breakthrough data for real-time parallel next generation sequencing DNA analysis of both ctDNA and CTCs from a single tube of patient blood, using a pan-cancer panel run on an Illumina NGS system.

Read more
4 Jan 2024 16:54

LONDON MARKET CLOSE: Stocks up ahead of US nonfarm payrolls

(Alliance News) - Stock prices in London closed higher on Thursday, as investors eye the latest US non-farms data.

Read more
4 Jan 2024 12:19

Angle shares soar following "breakthrough" cancer diagnostics results

(Alliance News) - Angle PLC on Thursday said that "breakthrough results" from its latest blood sample cancer trials would allow it to expand its product sales and pharma services.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.